In our study of P13, the first primary tumor (squamous cell carcinoma) was observed in November 2018; the second tumor (adenocarcinoma) with an EGFR L858R mutation was observed in March 2019, and the patient was diagnosed with MPLC; the third tumor (squamous cell carcinoma) was observed in October 2019 and had the same pathology as the first tumor (Figures 8A, B). This evidence concerns the gene EGFR and adenocarcinoma.